Filtered By:
Drug: Byetta

This page shows you your search results in order of date.

Order by Relevance | Date

Total 47 results found since Jan 2013.

External Validation of the BRAVO Diabetes Model Using the EXSCEL Clinical Trial Data
ConclusionsThis study demonstrates the feasibility of using the BRAVO model in settings where only fully de-identified patient-level data are available.
Source: Diabetes Therapy - July 11, 2023 Category: Endocrinology Source Type: research

Effects of GLP-1 receptor agonists on neurological complications of diabetes
AbstractEmerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impairment, and peripheral neuropathy. We found a total of 19 studies: 8 studies include stroke or ...
Source: Reviews in Endocrine and Metabolic Disorders - May 26, 2023 Category: Endocrinology Source Type: research

Effects of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) on Cardiac Structure and Function: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials
ConclusionGLP-1RA drugs may improve systolic and diastolic function in type 2 diabetes and reduce infarct size post-acute myocardial infarction with no demonstrable effect on cardiac function in heart failure. Tailored recommendations for the use of GLP-1RAs for cardioprotection should be considered for each patient ’s condition.
Source: Cardiovascular Drugs and Therapy - July 12, 2022 Category: Cardiology Source Type: research

Exenatide Linked to Less Hyperglycemia After Stroke Exenatide Linked to Less Hyperglycemia After Stroke
The diabetes drug may offer better control than insulin for hyperglycemia, a common condition following stroke that leads to worse outcomes.Medscape Medical News
Source: Medscape Cardiology Headlines - May 12, 2022 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis
Conclusion: Semaglutide should be considered when GLP-1 RAs are indicated for T2DM patients.
Source: Frontiers in Pharmacology - December 24, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy of a glucagon-like peptide-1 agonist and restrictive versus liberal oxygen supply in patients undergoing coronary artery bypass grafting or aortic valve replacement: study protocol for a 2-by-2 factorial designed, randomised clinical trial
The objective of this study is to determine the efficacy of the GLP-1-analogue exenatide versus placebo and restrictive oxygenation (50% fractional inspired oxygen, FiO2) versus liberal oxygenation (100% FiO2) in patients undergoing open heart surgery. Methods and analysis A randomised, placebo-controlled, double blind (for the exenatide intervention)/single blind (for the oxygenation strategy), 2x2 factorial designed single-centre trial on adult patients undergoing elective or subacute CABG and/or surgical AVR. Patients will be randomised in a 1:1 and 1:1 ratio to a 6-hour and 15 min infusion of 17.4 µg of exenatid...
Source: BMJ Open - November 5, 2021 Category: General Medicine Authors: Wiberg, S., Kjaergaard, J., Mogelvang, R., Moller, C. H., Kandler, K., Ravn, H., Hassager, C., Kober, L., Nilsson, J. C. Tags: Open access, Surgery Source Type: research

Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
CONCLUSIONSIn patients with T2DM and ASCVD, cluster analysis identified four clinically distinct groups. Further cardiovascular phenotyping is warranted to inform patient care and optimize clinical trial designs.
Source: Diabetes Care - October 29, 2021 Category: Endocrinology Source Type: research

Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials
Conclusions: This updated network meta-analysis reproduced the findings in the first network meta-analysis, and moreover revealed that sotagliflozin was one of the most effective drugs as for lowering MI, stroke, MACE, and HHF, whereas ertugliflozin was not. These findings will provide the according evidence regarding the usage of specific SGLT2 inhibitors and GLP-1 RAs in T2D patients for prevention of specific cardiorenal endpoints.
Source: Medicine - July 30, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research